American Society of Hematology

Evening Symposia

Friday, December 8, 6:00 p.m. - 10:00 p.m.

Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenström Macroglobulinemia and Amyloidosis (Part 2 of a 2-Part Series)

Register now

This activity is supported by educational grants from AbbVie Inc., Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology

Location: Atlanta Marriott Marquis
Room: Marquis C-D

This activity, the second of a proposed 2-part series, will attempt to address many of the most common practical issues faced by clinicians managing patients with multiple myeloma and related disorders including Waldenström macroglobulinemia and amyloidosis. To accomplish this goal, prior to the event RTP will recruit 5 general hematologic oncologists to serve as the project’s Planning Committee. These individuals will participate in several planning sessions intended to tease out the patient scenarios, management concerns and available data sets that pose the greatest challenge to their clinical decision-making. Utilizing this information as the basis for the agenda, the meeting, which will feature 5 renowned investigators as the program faculty, will employ a blend of short didactic presentations, interactive audience polling utilizing networked tablets and extensive moderated panel discussion to provide perspectives on new and emerging research and address many of the real-world concerns voiced by the Planning Committee members. A video-recorded capture of the program will be distributed as an enduring CME activity to deliver the valuable and practical information that emerges to a larger worldwide audience.

Program Chair
Neil Love, MD, Research To Practice, Miami, FL

Speakers

  • Meletios Dimopoulos, University of Athens School of Medicine, Kifissia
  • Sagar Lonial, MD, Winship Cancer Institute, Emory University, Atlanta, GA
  • Nikhil C Munshi, MD, Harvard Medical School, Boston, MA
  • Robert Z Orlowski, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Noopur Raje, MD, Harvard Medical School, Boston, MA

Contact
Sylvia Eriksen
Research To Practice
305-377-2828
seriksen@researchtopractice.com

back to top

Advancing Standards in the Management of Hemophilia A: Contemporary Strategies and Innovations

Register now

This program is sponsored by CMEology and supported by Shire.

Location: Hyatt Regency Atlanta
Room: International Ballroom North

The US health care ecosystem has undergone a profound transformation in recent years, with far-reaching implications for patients with hemophilia A. Clinical management of patients with hemophilia has become increasingly complex due to the introduction of new treatment strategies, the presence of comorbidities related to hemophilia, and the increased emphasis on outcomes such as quality of life to balance both the medical and lifestyle consequences of the disease. Patients with severe hemophilia have the greatest need for comprehensive care including primary prophylaxis, overcoming problems relating to inhibitor development, and monitoring for arthropathies. The comprehensive care model focuses on the prevention of morbidity and mortality while promoting a high quality of life characterized by a lifestyle that overcomes the limitations of hemophilia. The application of contemporary strategies and recent innovations provides new hope to prevent subclinical bleeding, achieve zero bleeds, and optimize care for every individual with hemophilia A.

In this symposium, expert faculty will provide an update on the state-of-the-art advancements in the management of patients with hemophilia A to decrease the burden of disease.

Program Chair
Steven W. Pipe, MD, University of Michigan Medical Center, Ann Arbor, MI

Speakers

  • Erik Berntorp, MD, PhD, Lund University, Malmö, Sweden, Malmö
  • Cindy A. Leissinger, MD, Tulane University School of Medicine, New Orleans, LA

Contact
Robert Lowney
CMEology
860-236-1200
rlowney@cmeology.org

back to top

Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic Malignancies

Register now

This program is sponsored by Physicians' Education Resource, LLC (PER) and supported by Sandoz.

Location: Georgia World Congress Center
Room: A402-403

Participants of this educational curriculum will be brought up to date on the most recent clinical advances in emerging biosimilar agents, efficacy and safety of such agents, and patient counseling strategies that will potentially impact treatment and management of patients with hematologic malignancies. The symposium is designed to educate audiences in an innovative, engaging format and will include a mix of didactic lecture, case-studies that reflect challenges among community hematologists when deciding clinical trial options for patients, panel discussion and Q&A. Case-studies and panel discussions will be used by the Chair to challenge faculty on their treatment decisions and to give the opportunity for the audience to reflect on best practices and their own clinical decisions for higher educational engagement.

Program Chair
Edward Li, PharmD, MPH, BCOP, University of New England, Portland, ME

Speakers

  • Andrew D. Zelenetz, MD, PhD, Department of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Pamela S. Becker, MD, PhD, University of Washington, Seattle, WA
  • Bertrand Coiffier, MD, PhD, Centre Hospitalier Lyon-Sud, Pierre-Benite

Contact
Stephanie Neumann
Physicians' Education Resource, LLC (PER)
609-716-7777
sneumann@gotoper.com

back to top

Hematologic Malignancies in the Era of Immunotherapy: Clinician and Patient Perspectives

Register now

This program is sponsored by prIME Oncology and supported by Bristol-Meyers Squibb.

Location: Hyatt Regency Atlanta
Room: Centennial I

This engaging satellite symposium has been designed to provide participants with an overview of the evolving treatment landscape of multiple myeloma, Hodgkin lymphoma, chronic myeloid leukemia, and acute myeloid leukemia, and where immunotherapies are currently indicated or potentially indicated in the near future. Compelling patient video snippets (de-identified patients; HIPAA compliant) introduce each segment of the activity, followed by immunotherapy experts informing on important updates in each field and discussing practice challenges.

Speakers

  • Andreas Engert, MD, University Hospital Cologne, Cologne
  • Jorge E Cortes, MD, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Michael J. Mauro, MD, Memorial Sloan-Kettering Cancer Center, New York, NY
  • Donna Reece, MD, Princess Margaret Cancer Centre, Toronto, ON

Contact
Emily Simpson
prIME Oncology
470-685-9205
Emily.simpson@primeoncology.org

back to top

Incorporating New Therapeutic Strategies in the Treatment of Hodgkin Lymphoma

Register now

This program is sponsored by Clinical Care Options and supported by Seattle Genetics, Takeda Oncology, and Merck, Inc.

Location: Atlanta Marriott Marquis
Room: Imperial A

This symposium provides the perfect opportunity for attendees to hear about the latest practice-changing data as well as emerging novel agents and combination regimens for Hodgkin lymphoma (HL) in preparation to incorporate these therapeutic advances in clinic. Symposium participants will enjoy an engaging program format featuring limited didactic data review with time specifically devoted to case discussion among a panel of 4 internationally renowned lymphoma experts. Participants will be presented with a series of case challenges followed by management questions. After participants vote on the cases, the panelists will discuss the available evidence and guidelines along with a summary of their individual treatment recommendations for each case. The panelists will be asked to defend the rationale for their treatment recommendations and will debate differing opinions. Topics will include:

  • How Should You Individualize Initial Therapy for Early and Advanced Disease?
  • Should We Be Using Response-Adapted Therapy in Clinical Practice?
  • How Can We Minimize Second Relapse After Stem Cell Transplantation in Clinical Practice?
  • How Should You Individualize Therapy for Relapsed/Refractory Disease?

Program Chair
Ranjana H Advani, MD, Stanford University Medical Center, Stanford, CA Speakers

Speakers

  • Robert W Chen, MD, City of Hope, Duarte, CA
  • Pier Luigi Zinzani, MD, PhD, Institute of Hematology Seràgnoli, University of Bologna, Bologna
  • Andrew M Evens, DO, MSc, FACP, Tufts University School of Medicine and Cancer Center, Boston, MA

Contact
Clinical Care Options Registration
https://www.clinicaloptions.com/event/HLSatellite2017

For help with registering, call 1-855-224-2241
(9:00 AM – 5:00 PM Eastern, weekdays)

back to top

Illuminating the Role of Shared Decision-Making as the Hemophilia A Management Landscape Continues to Evolve: Progress in Practice

Register now

This program is sponsored by PeerView Institute for Medical Education and supported by Genentech Inc.

Location: Hyatt Regency Atlanta
Room: Regency VI

While the introduction of recombinant clotting factor VIII (FVIII) in the early 1990s facilitated the use of prophylaxis as the standard care rather than on-demand treatment, a number of barriers to their optimal use persist in patients with hemophilia A; the development of inhibitors is perhaps the most problematic. Fortunately, novel therapeutic approaches seek to improve upon many of the shortcomings of standard plasma-derived or recombinant clotting factor prophylaxis by several different mechanisms, including extending the half-life of circulating exogenous factor protein, and non-clotting factor approaches such as bispecific antibody technology and anticoagulant blockade. These new and emerging treatment options may reduce the frequency of clotting factor infusions; nonfactor replacement strategies may also prove to be promising approaches for patients with inhibitors. Given the expanding number of therapeutic options, shared decision-making between clinicians, patients, and their caregivers has become increasingly critical.

PeerView’s live symposium will offer expert perspective on these advances and outline the future of hemophilia A management by featuring analyses of the latest, updated clinical evidence on modified replacement clotting factors and nonfactor replacement strategies, as well as the increasing role of shared decision-making as the number of management strategies for hemophilia A continues to evolve.

Program Chair
Guy Young, MD, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA

Speakers

  • Johannes Oldenburg, MD, PhD, Institute of Experimental Hematology and Transfusion Medicine, Bonn
  • Rebecca Kruse-Jarres, MD, MPH, University of Washington School of Medicine, Seattle, WA

Contact
Cassie Rametta
PeerView Institute for Medical Education
1-877-833-6141
live@peerview.com

back to top

Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients

Register now

This program is sponsored by Clinical Care Options and supported by Daiichi Sankyo, Inc., Jazz Pharmaceuticals, Inc., and Pfizer Inc.

Location: Atlanta Marriott Marquis
Room: Atrium A

New advances in efficacious and better tolerated therapies, plus the development of predictive and prognostic factors, are allowing for the individualization of therapy for patients with acute myeloid leukemia (AML). This symposium will focus on the dramatic and rapid changes occurring in the treatment of AML and will feature limited didactic presentations with time devoted to discussion among a panel of experts. The symposium format is engaging and actively involves participants in the program, allowing direct interaction with the panelists. Participants will be presented with a series of case examples followed by management questions. After participants vote on the cases, the panelists will discuss the available data along with a summary of their individual treatment recommendations for each case. The panelists will be asked to defend the rationale for their treatment recommendations and will debate differing opinions. This program will not be a “data dump”; it will instead have content and expert insights focused specifically on application of new data to the clinic. Potential topics include: predictive/prognostic factors for AML, management of newly diagnosed AML, treatment of relapsed/refractory disease, and the latest clinical trial data on novel agents that may affect care in the near future.

Program Chair
Jeffrey E. Lancet, MD, Moffitt Cancer Center, Tampa, FL

Speakers

  • B. Douglas Smith, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD
  • Gail J. Roboz, MD, Weill Cornell Medical College New York, NY
  • Roland B. Walter, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA

Contact Clinical Care Options Registration
https://www.clinicaloptions.com/event/AMLSatellite2017

For help with registering, call 1-855-224-2241
(9:00 AM – 5:00 PM Eastern, weekdays)

back to top

Redefining Patient Care in Acute Lymphoblastic Leukemia: The Impact of Novel Antibody and Immune Technologies on Clinical Outcomes

Register now

This program is sponsored by PeerView Institute for Medical Education and supported by Pfizer Inc.

Location: Hyatt Regency Atlanta
Room: Centennial IV

New science is poised to change the way patients with acute lymphoblastic leukemia (ALL) are treated, particularly adult patients who have not consistently benefited from standard pediatric-derived chemotherapy protocols. Many factors have contributed to this imminent evolution in ALL care, including a modern understanding of minimum residual disease (MRD) as a prognostic factor and the rapid development of antibody- and immune-based treatments. Now, new scientific vistas are opening up in ALL based on the ability of new antibody technologies to enhance outcomes, as well as the potential effectiveness of chimeric antigen receptor (CAR) T cell therapy; these exciting strategies are now being assessed as components in novel combination regimens or as strategies to eradicate MRD.

PeerView’s live symposium will offer expert takes on these clinical trends and map out the future of ALL treatment by featuring analyses of the latest, updated clinical evidence on antibodies and CAR T cell therapy, as well as a look at key ongoing studies combining antibodies with other modalities in ALL populations who require better and more effective treatments.

Program Chair
Daniel J. DeAngelo, MD, PhD, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

Speakers

  • Stephan A. Grupp, MD, PhD, University of Pennsylvania Perelman School of Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA
  • Mark R. Litzow, MD, Mayo Clinic, Rochester, MN
  • Charles G. Mullighan, MBBS (Hons), MSc, MD, St. Jude Children's Research Hospital, Memphis, TN

Contact
Cassie Rametta
PeerView Institute for Medical Education
1-877-833-6141
live@peerview.com

back to top

back to top